Comera Life Sciences (CMRA) Competitors $0.0001 0.00 (-50.00%) As of 04/29/2025 02:27 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock CMRA vs. CALA, SCPS, EVLO, SMFL, GNCAQ, GNCA, ARDS, STAB, AMPE, and EFTRShould you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Smart for Life (SMFL), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Comera Life Sciences vs. Calithera Biosciences Scopus BioPharma Evelo Biosciences Smart for Life Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals eFFECTOR Therapeutics Comera Life Sciences (NASDAQ:CMRA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations. Does the media favor CMRA or CALA? In the previous week, Calithera Biosciences had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Comera Life Sciences. Comera Life Sciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Calithera Biosciences Neutral Which has better earnings & valuation, CMRA or CALA? Comera Life Sciences has higher revenue and earnings than Calithera Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00M0.00-$18MN/AN/ACalithera BiosciencesN/AN/A-$39.65MN/AN/A Does the MarketBeat Community prefer CMRA or CALA? Calithera Biosciences received 341 more outperform votes than Comera Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperformComera Life SciencesN/AN/ACalithera BiosciencesOutperform Votes34155.36% Underperform Votes27544.64% Which has more risk & volatility, CMRA or CALA? Comera Life Sciences has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -1.13, indicating that its share price is 213% less volatile than the S&P 500. Is CMRA or CALA more profitable? Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Calithera Biosciences N/A N/A N/A SummaryComera Life Sciences beats Calithera Biosciences on 3 of the 5 factors compared between the two stocks. Get Comera Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRA vs. The Competition Export to ExcelMetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3,000.00$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / Sales0.00241.49397.62103.30Price / CashN/A65.8538.1834.62Price / BookN/A6.486.734.25Net Income-$18M$143.41M$3.22B$248.18M7 Day PerformanceN/A2.58%1.38%1.03%1 Month PerformanceN/A5.00%2.79%2.70%1 Year PerformanceN/A-3.72%15.41%4.05% Comera Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRAComera Life SciencesN/A$0.00-50.0%N/A-99.7%$3,000.00$1.00M0.002Gap DownHigh Trading VolumeCALACalithera BiosciencesN/A$0.01flatN/AN/A$24,000.00N/A0.0060SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/A-98.9%$9,000.00N/A0.00120Options VolumeSMFLSmart for LifeN/A$0.00+150.0%N/A-100.0%$7,000.00$11.11M0.00110Gap UpGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070ARDSAridis PharmaceuticalsN/AN/AN/A-99.8%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020High Trading VolumeAMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.8%$2,000.00N/A0.0020EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-100.0%$1,000.00$3.55M0.0010Gap UpHigh Trading Volume Related Companies and Tools Related Companies CALA Competitors SCPS Competitors EVLO Competitors SMFL Competitors GNCAQ Competitors GNCA Competitors ARDS Competitors STAB Competitors AMPE Competitors EFTR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMRA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMRA Stock Free CMRA Stock Alerts